AVDL · As filed with the SEC

Avadel Pharmaceuticals cash flow statement, by quarter

The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands

USD thousands	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024
Cash flows from operating activities:
Net income (loss)	20^†	9,665^†	(4,920)	(5,043)^†
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,115^†	1,068^†	825	668^†
Amortization of debt discount and debt issuance costs	—	—	—	0^†
Share-based compensation expense	4,919^†	5,327^†	4,183	4,126^†
Loss on extinguishment of debt	—	—	—	0^†
Other adjustments	(262)^†	(856)^†	70	224^†
Net changes in assets and liabilities
Accounts receivable	(1,813)^†	950^†	(7,484)	3,005^†
Inventories	(681)^†	(3,295)^†	(66)	(3,964)^†
Prepaid expenses and other current assets	842^†	612^†	(3,016)	2,031^†
Accounts payable & other current liabilities	2,289^†	999^†	1,779	(577)^†
Accrued expenses	(3,572)^†	1,859^†	218	6,744^†
Other assets and liabilities	(652)^†	(3,632)^†	179	659^†
Net cash provided by (used in) operating activities	22,205^†	12,697^†	(8,232)	7,873^†
Cash flows from investing activities:
Purchases of property and equipment	(9)^†	—	—	0^†
Proceeds from sales of marketable securities	11,800^†	28,130^†	17,808	28,952^†
Purchases of marketable securities	(5,224)^†	(36,203)^†	(5,491)	(14,039)^†
Net cash (used in) provided by investing activities	(8,433)^†	(8,254)^†	12,317	14,913^†
Cash flows from financing activities:
Proceeds from issuance of shares off the at-the-market offering program	0^†	0^†	0	—
At-the-market offering program	—	—	—	0^†
Public offering	—	—	—	0^†
Proceeds from stock option exercises and employee share purchase plan	2,507^†	982^†	690	880^†
Payments for debt issuance costs	—	—	—	0^†
Proceeds from royalty purchase agreement	—	—	—	0^†
Net cash provided by financing activities	2,507^†	982^†	690	880^†
Effect of foreign currency exchange rate changes on cash and cash equivalents	132^†	1,607^†	224	(877)^†
Net change in cash and cash equivalents	16,411^†	7,032^†	4,999	22,789^†
Cash and cash equivalents at January 1,	63,402	56,370	51,371	28,582
Cash and cash equivalents at September 30,	79,813	63,402	56,370	51,371
Supplemental disclosures of cash flow information:
Interest paid	2,555^†	1,969^†	1,890	3,876^†

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.